Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00640458 |
The purpose of this study is to investigate the effect of 100 mg sildenafil on clitoral engorgement in pre-menopausal women, as well as examining the safety and toleration of the drug.
Condition | Intervention | Phase |
---|---|---|
Female Sexual Arousal Disorder |
Drug: Sildenafil 100 mg Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Crossover Assignment, Safety/Efficacy Study |
Official Title: | A Double Blind, Placebo Controlled 2-Way Cross-Over Study to Assess the Clitoral Engorgement Response as Measured by Non-Contrast Magnetic Resonance Imaging (MRI) in Women With Female Sexual Arousal Disorder (FSAD) When Administered a Single Dose of Sildenafil (100mg) Followed by Audio/Visual Sexual Stimulation |
Enrollment: | 20 |
Study Start Date: | April 2004 |
Study Completion Date: | March 2007 |
Arms | Assigned Interventions |
---|---|
Placebo: Placebo Comparator
Study Period 1 or 2
|
Drug: Placebo |
Experimental: Experimental
Study Period 1 or 2
|
Drug: Sildenafil 100 mg |
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Washington | |
Pfizer Investigational Site | |
Seattle, Washington, United States, 98105 | |
Pfizer Investigational Site | |
Seattle, Washington, United States, 98195-6465 | |
Australia, Western Australia | |
Pfizer Investigational Site | |
Nedlands, Western Australia, Australia, 6009 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer Inc ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A1481174 |
Study First Received: | March 17, 2008 |
Last Updated: | April 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00640458 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Genital Diseases, Female Sexual Dysfunctions, Psychological Vasodilator Agents Hyperemia Phosphodiesterase Inhibitors Sexual Dysfunction, Physiological |
Mental Disorders Sildenafil Cardiovascular Agents Genital Diseases, Male Menopause |
Sexual Dysfunctions, Psychological Vasodilator Agents Disease Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Sildenafil Cardiovascular Agents Genital Diseases, Male |
Sexual and Gender Disorders Pharmacologic Actions Genital Diseases, Female Phosphodiesterase Inhibitors Sexual Dysfunction, Physiological Pathologic Processes Mental Disorders Therapeutic Uses |